BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
16.44
+0.78 (+4.98%)
At close: 3:46PM EDT
Stock chart is not supported by your current browser
Previous Close15.66
Open15.97
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.88 - 16.44
52 Week Range14.61 - 28.19
Volume702,191
Avg. Volume992,554
Market Cap61.752B
Beta (3Y Monthly)1.00
PE Ratio (TTM)8.91
EPS (TTM)1.84
Earnings DateN/A
Forward Dividend & Yield0.78 (5.00%)
Ex-Dividend Date2019-04-29
1y Target Est21.50
Trade prices are not sourced from all markets
  • These four companies control the world's food chain
    Yahoo Finance Video15 days ago

    These four companies control the world's food chain

    Consolidation in the seed industry has put these four companies in charge of the global food chain. Yahoo Finance's Julie Hyman, Adam Shapiro, Brian Sozzi and Dan Barber Co-founder of Row 7 Seed Company, Chef and co-owner of the Blue Hill and Blue Hill at Stone Barns discuss.

  • Bloomberg1 hour ago

    Elliott Says It Holds Stake in Bayer and Sees Value Potential

    (Bloomberg) -- Elliott Management Corp. disclosed a 1.1 billion euro ($1.3 billion) stake in Bayer AG and said the company could unlock about 30 billion euros in shareholder value once it puts to rest litigation over the Roundup weedkiller.Bayer’s moves to bolster its response to the wave of Roundup lawsuits, including hiring high-profile lawyer John Beisner as an adviser, are a “step change,” the New York-based activist hedge fund said in a statement Wednesday. The German company has been dogged by investor unrest since last year’s $63 billion takeover of agricultural giant Monsanto.Disgruntled investors rebuked Bayer’s management and supervisory board at its annual shareholder meeting in April, as judgments mount from claims that Monsanto’s herbicide, whose active ingredient is the chemical glyphosate, causes cancer. The German company has already lost three suits in U.S. courts, and the costs of settling the remainder have been estimated in the range of $10 billion. The company says that studies show no link between glyphosate and cancer.“While resolving the litigation challenge is clearly an immediate priority, Elliott believes Bayer could do more to maximize long-term value for all its stakeholders,” the hedge fund said in a statement. “Bayer’s discounted share price today does not reflect the significant underlying value of its constituent businesses, or the potential value realization opportunity.”The firm did not detail how Bayer could unlock the value of its underlying assets. It said it looks forward to Bayer building on the announcement with a commitment to the exploration of “long-term value creative levers” beyond the immediate governance and litigation issues.Bayer said it plans to set up a supervisory board committee dedicated to handling the more than 13,400 U.S. plaintiffs claiming that Roundup caused their cancer, according to a statement Wednesday. The company said Beisner, of the Skadden Arps Slate Meagher & Flom law firm, will advise the committee, and that it’s looking to further bolster its board with regard to food and agriculture.Beisner “will provide very valuable and concrete advice on the ongoing litigation as well as the mediation,” said Werner Wenning, chairman of the supervisory board.Some large shareholders have pressured Bayer to take a more proactive approach to resolving the lawsuits as well as considering strategic changes including a breakup into separately listed pharma and crop science companies, people familiar with the situation have said.To contact the reporters on this story: Eyk Henning in Frankfurt at ehenning1@bloomberg.net;Scott Deveau in New York at sdeveau2@bloomberg.net;Tim Loh in Munich at tloh16@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, John Lauerman, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Bayer seeks glyphosate litigation advice as Elliott reveals stake
    Reuters2 hours ago

    Bayer seeks glyphosate litigation advice as Elliott reveals stake

    Chemicals giant Bayer, under pressure from activist shareholders, said on Wednesday it has hired an external lawyer to advise its supervisory board and has set up a committee to help resolve a multi-billion dollar glyphosate litigation issue. Bayer has seen its share price tumble in the wake of its $63 billion acquisition of Monsanto, which brought with it massive legal issues after more than 13,400 plaintiffs alleged the company's glyphosate weedkiller caused cancer. Bayer, which acquired Monsanto last year, says studies and regulators have deemed glyphosate and Monsanto's Roundup weedkiller safe for human use, but the German company has struggled to contain the reputational and legal fallout.

  • Reuters2 hours ago

    UPDATE 2-Bayer seeks glyphosate litigation advice as Elliott reveals stake

    Chemicals giant Bayer , under pressure from activist shareholders, said on Wednesday it has hired an external lawyer to advise its supervisory board and has set up a committee to help resolve a multi-billion dollar glyphosate litigation issue. Bayer has seen its share price tumble in the wake of its $63 billion acquisition of Monsanto, which brought with it massive legal issues after more than 13,400 plaintiffs alleged the company's glyphosate weedkiller caused cancer.

  • Reuters3 hours ago

    Bayer's supervisory board hire lawyer for glyphosate litigation

    German chemicals giant Bayer on Wednesday said its supervisory board will form a committee to address glyphosate litigation, retaining a lawyer to give a fresh perspective on how to resolve a multi-billion dollar legal problem. Bayer said it has hired U.S. lawyer John H. Beisner to advise the Supervisory Board on matters related to the glyphosate litigations, including trial tactics and mediation, on an ongoing basis. "His appointment is intended to add fresh and independent perspectives to the advice given to the Board of Management," the company said in a statement on Wednesday.

  • Glyphosate use will eventually end, Merkel says
    Reuters7 hours ago

    Glyphosate use will eventually end, Merkel says

    Use of Bayer's contested weedkiller glyphosate, the subject of more than 10,000 lawsuits in the U.S. over claims it causes cancer, will eventually die out, German Chancellor Angela Merkel told the country's lower house on Wednesday. Merkel's view is seemingly at odds with that of Bayer, which acquired the pesticide along with its takeover of U.S. seed maker Monsanto, which earlier this month said it saw a future for the product. Bayer's shares hit seven-year lows after a California couple was last month awarded more than $2 billion in the largest-ever U.S. jury award over claims that glyphosate-based weedkiller Roundup, caused their cancer.

  • Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down
    Zacksyesterday

    Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

    Bristol-Myers (BMY) declines as it announces to sell Otezla to settle FTC concerns, while Opdivo fails in liver cancer study.

  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch4 days ago

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • Bayer asks trial judge to reverse $2 billion Roundup jury verdict
    Reuters8 days ago

    Bayer asks trial judge to reverse $2 billion Roundup jury verdict

    The German drugmaker and chemicals company in court filings on Monday in Alameda County Superior Court in Oakland blamed the massive verdict on "inflammatory, fabricated and irrelevant evidence" from the couples' lawyers. "The resulting trial focused not on ascertaining the truth regarding the state of the science, causation, and compliance with legal duties, but instead on vilifying Monsanto in the abstract," the company, which bought Monsanto last year for $63 billion, said in motions filed with the court. The verdict and two prior jury decisions against Bayer have triggered steep declines in Bayer shares, leaving it with a market valuation of $56 billion.

  • Financial Times8 days ago

    Fosun/Bayer: pet project

    China has the world’s third-largest number of cat and dog owners. Keeping pets flea-free is a priority. Acquisitive Chinese investment group Fosun International is reportedly on the lookout for ways to ...

  • China's Fosun Mulls Joint Bid for Bayer Animal Health Arm
    Bloomberg8 days ago

    China's Fosun Mulls Joint Bid for Bayer Animal Health Arm

    (Bloomberg) -- Fosun International Ltd. is considering a bid for Bayer AG’s animal-health business, people familiar with the matter said, a move that could mark a return to big-ticket deals for the Chinese conglomerate backed by billionaire Guo Guangchang.Fosun has held talks with potential advisers and is considering teaming up with private equity firms or other financial investors for a joint offer, the people said. Bayer could start the sale process as soon as the next few weeks, the people said, asking not to be identified because the matter is private.The animal-health business could fetch as much as 8 billion euros ($9 billion) and has drawn preliminary interest from potential bidders including KKR & Co., CVC Capital Partners, Advent International, Blackstone Group LP, EQT Partners and Permira, Bloomberg News has reported.The last time Fosun announced a billion-dollar takeover was nearly three years ago, before Beijing began clamping down on some serial Chinese acquirers, data compiled by Bloomberg show. The government has sought to limit frothy purchases overseas and restricted deals in certain industries after high-profile global buying sprees by some Chinese firms such as Anbang Insurance Group Co. left them saddled with debt.Fosun Co-President Xu Xiaoliang said in a September 2017 interview that it remains on course to expand its footprint globally, focusing on sectors the government has indicated it would approve of. It still has appetite for more investments: Fosun disclosed last year that it looks at an average of 9,000 potential transactions annually, though it only completes about 100.Shares of Fosun International have fallen 38% in the past year, compared with a 7.6% decline in the benchmark Hang Seng Index.Bayer’s animal-health unit sells veterinary products for both pets and livestock. Its best-selling product line is the Advantage flea, tick and worm treatment for small animals. Fosun could help further expand Bayer’s existing business in Asian markets including China, the people said.Deliberations are at an early stage, and Fosun could still decide against pursuing a formal bid, the people said. A representative for Fosun said the company has no information to disclose, while a representative for Bayer declined to comment.The German drug and chemical company is under pressure to raise cash and streamline its business portfolio as it wrestles with the fallout from its $63 billion takeover of Monsanto Co. In May, it agreed to sell its Coppertone brand of sun-care products to Beiersdorf AG for $550 million.Other European companies have also been preparing disposals amid pressure from investors to rekindle growth. Last month, Nestle SA entered exclusive talks to sell its skincare business to a group led by EQT and the Abu Dhabi Investment Authority for 10.2 billion Swiss francs ($10 billion).(Updates to add Fosun share price in sixth paragraph.)\--With assistance from Tim Loh, Dong Lyu and Dinesh Nair.To contact the reporter on this story: Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.netTo contact the editors responsible for this story: Fion Li at fli59@bloomberg.net, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Bayer to Invest 5 Billion Euros in Weedkiller Research
    Zacks9 days ago

    Bayer to Invest 5 Billion Euros in Weedkiller Research

    Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.

  • Will Bayer's Investment in its Reputation Boost BAYRY Stock?
    Zacks9 days ago

    Will Bayer's Investment in its Reputation Boost BAYRY Stock?

    Bayer (BAYRY) announced last Friday that it is set to invest approximately 5 billion euros, or around $5.6 billion, in order to further research "additional methods to combat weeds."

  • Financial Times12 days ago

    Bayer to invest €5bn in alternative weedkillers

    German pharma and chemicals giant Bayer is pumping €5bn into developing new weedkillers as part of efforts to deal with the fallout from lawsuits claiming its glyphosate-based weedkillers cause cancer. Shortly after the deal was completed, a US jury ruled that two key Monsanto products — Roundup and Ranger Pro, both glyphosate-based weedkillers — were linked to cancer. Bayer faces more than 13,000 similar claims in US courts.

  • Bayer to invest $5.6 billion in weedkiller research to help reputation
    Reuters12 days ago

    Bayer to invest $5.6 billion in weedkiller research to help reputation

    Germany's Bayer sought to repair its reputation on Friday after damage caused by U.S. litigation over claims its glyphosate pesticide causes cancer, saying it would invest 5 billion euros ($5.6 billion) in weedkiller research. Bayer's shares hit seven-year lows after a California couple was last month awarded more than $2 billion in the largest-ever U.S. jury award over claims that glyphosate-based weedkiller Roundup, which the German life sciences group acquired when it took over Monsanto, causes cancer. As well as saying it would invest 5 billion euros in research over the next ten years, Bayer promised to reduce its environmental impact by 30% through 2030 via measures such as more precise and more sparing application of crop chemicals.

  • Reuters12 days ago

    UPDATE 2-Bayer to invest $5.6 bln in weedkiller research to help reputation

    Germany's Bayer sought to repair its reputation on Friday after damage caused by U.S. litigation over claims its glyphosate pesticide causes cancer, saying it would invest 5 billion euros ($5.6 billion) in weedkiller research. Bayer's shares hit seven-year lows after a California couple was last month awarded more than $2 billion in the largest-ever U.S. jury award over claims that glyphosate-based weedkiller Roundup, which the German life sciences group acquired when it took over Monsanto, causes cancer. As well as saying it would invest 5 billion euros in research over the next ten years, Bayer promised to reduce its environmental impact by 30% through 2030 via measures such as more precise and more sparing application of crop chemicals.

  • Financial Times12 days ago

    Bayer/glyphosate: weedy response

    Campaigners globally want to ban its main ingredient. Bayer’s move concerning glyphosate, a controversial weedkiller, created good publicity. Bayer’s market value has dropped 45 per cent, or €40bn, since the deal closed, making it among the most value-destroying in history.

  • Reuters15 days ago

    UPDATE 2-Trump simplifies reviews of genetically modified farm products

    U.S. President Donald Trump signed an executive order on Tuesday directing federal agencies to streamline the review process for agricultural biotechnology including genetically modified livestock and seeds. Trump signed the order during a visit to an ethanol plant in Council Bluffs, Iowa.

  • How consolidation in the seed industry is jeopardizing our future food supply
    Yahoo Finance15 days ago

    How consolidation in the seed industry is jeopardizing our future food supply

    Dan Barber, co-founder of Row 7 Seed Company and chef and co-owner of the Blue Hill and Blue Hill at Stone Barns restaurants, highlights how consolidation in the agriculture space, in which four companies control the seed market, will pose a problem for the future of food.

  • Reuters16 days ago

    Defying law, Indian farm group says it planted unapproved GM cotton seeds

    An Indian farm group said its members had planted a variety of genetically modified cotton seeds which have not been approved by the country's government, an offence that could result in five years imprisonment. It is the first time farmers, who argue that they shouldn't be deprived of any new technology, have acknowledged planting the herbicide-tolerant cotton variety, which was developed by German drugmaker Bayer AG's Monsanto unit. Industry officials estimate the area planted with such seeds reached at least 10 percent of the 12.2 million hectares of Indian cotton acreage in 2018 and Anil Ghanwat, president of the Shetkari Sangathana farmers union, said there is likely to be an increase this year.

  • CRISPR Therapeutics Up on Collaboration Expansion by Vertex
    Zacks16 days ago

    CRISPR Therapeutics Up on Collaboration Expansion by Vertex

    CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.

  • Reuters18 days ago

    USDA investigates unapproved GMO wheat found in Washington state

    The U.S. Department of Agriculture has confirmed the discovery of unapproved, genetically modified (GM) wheat plants growing in an un-planted agricultural field in Washington state. There was no evidence the wheat had entered the food supply, the USDA's Animal and Plant Health Inspection Service said in a statement on Friday. "USDA is collaborating with our state, industry and trading partners, and we are committed to providing all our partners with timely and transparent information about our findings," the statement said.

  • Blueprint Medicines to File NDA for Avapritinib With FDA
    Zacks21 days ago

    Blueprint Medicines to File NDA for Avapritinib With FDA

    Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.